hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06384690 id: 4331899 briefTitle: Generating Health Evidence From Dietary Supplementation With a Micro-vegetable Blend overallStatus: RECRUITING date: 2024-02-01 date: 2024-11-30 date: 2025-08-31 date: 2024-04-25 date: 2024-04-25 name: University of Exeter class: OTHER name: Advanced Growers Limited name: Ecog Pro Limited briefSummary: Micro-vegetables (MV) are seedlings of larger vegetables. They can be grown quickly and are a concentrated source of micronutrients. MV are thought to have broad health benefits, including many inflammatory conditions. These include metabolic, cardiovascular, and cognitive diseases. This could have important implications for the health of an ageing UK population. Less than a third of British adults consume 5 portions of fruit and vegetables per day; this is the level that reduces risk of morbidity and mortality. Vegetables, including MV may - at least in part - exert their health effects by changing the level and type of bacteria in the mouth and gut. Despite their promise, the MV scientific literature is not yet extensive enough to support definitive health claims. It requires the addition of high-quality studies that are relevant to humans. This study will firstly investigate the anti-inflammatory effects on skeletal muscle and adipose tissue in older adults, using a proteomics approach. Second, this study will assess concentrations of circulating inflammatory markers in the sera collected from participants at baseline and at the conclusion of a 6-week period. Further, this study will describe the effects of six weeks MV consumption on cognition, and the oral and gut microbiome. As the bioactive compounds in the MV are owed to the potential beneficial effects for human health, these will be characterised in sera collected from participants. conditions: Inflammation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 30 type: ESTIMATED name: Micro-vegetable blend name: Placebo measure: Tandem Mass Tag (TMT) global proteomics measure: Concentration of broad panel of inflammatory cytokines measure: Concentration of circulating bioactive components measure: Microbiome measure: Simple Reaction Time measure: Digit Vigilance measure: Choice Reaction Time measure: Pattern Separation sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Public Health and Sports Sciences, University of Exeter status: RECRUITING city: Exeter state: Devon zip: EX1 2LU country: United Kingdom name: Cealan Henry role: CONTACT email: c.henry3@exeter.ac.uk lat: 50.7236 lon: -3.52751 hasResults: False
nctId: NCT06384677 id: 03.03.2023/371 briefTitle: Comparison of Postoperative Analgesia Methods in Patients Undergoing Major Intraabdominal Surgery overallStatus: COMPLETED date: 2023-04-20 date: 2024-02-01 date: 2024-02-01 date: 2024-04-25 date: 2024-04-25 name: Marmara University class: OTHER briefSummary: This study aims to examine the effects of M-TAPA applied for postoperative analgesia in patients who had major intraabdominal surgery on the postoperative pain score, the change in the postoperative total opioid requirement and the side effects. conditions: Abdominal Cancer conditions: Abdomen Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 43 type: ACTUAL name: M-Tapa Block measure: Opioid Consumption measure: NRS Scores measure: the need for rescue analgesia measure: side effects sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Marmara University Pendik Research and Training Hospital city: Istanbul country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06384664 id: HUM00241242 briefTitle: Cryoablation Effects on Acute and Chronic Pain After Thoracotomy and Thoracoscopy overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-04 date: 2028-04 date: 2024-04-25 date: 2024-04-25 name: University of Michigan class: OTHER name: AtriCure, Inc. briefSummary: The researchers will compare the common methods of post-surgical pain control, such as epidural or intercostal nerve block with a newer method called cryoablation. The research team is conducting this study to determine if cryoablation provides more effective pain control when compared to an epidural or intercostal nerve block. conditions: Pain, Postoperative conditions: Intrathoracic Procedure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 80 type: ESTIMATED name: Atricure's crysoSPHERE probe name: Standard of Care measure: Severity of pain in the peri-operative period measure: Inflammatory cytokine levels as measured by blood samples measure: Inflammatory cytokines (IL-1, IL-6, TNF-a) levels correlations to pain score measure: Peri-operative pain scores between different surgical incisions (posterolateral thoracotomy vs thoracoscopy) measure: Peri-operative nerve function between different surgical incisions (posterolateral thoracotomy vs thoracoscopy) measure: Quality of life score as measured by SF-36 Health questionnaire measure: Cost (including postoperative epidural management, narcotic pain medication, and outpatient pain management) measure: Workflow/time measure: Complications following surgery measure: Length of stay measure: Time to ambulation measure: Chronic Pain medication use through 6 months measure: Chronic pain through 6 months. measure: Chronic pain through 6 months. measure: Chronic pain through 6 months. measure: Incentive spirometry volumes in the peri-operative period (POD 1 and 2) measure: Oxygen requirement measure: Hospital charges and hospital reimbursement by different payors sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Michigan city: Ann Arbor state: Michigan zip: 48109 country: United States name: Shari L Barnett role: CONTACT phone: 734-936-4561 email: shbailey@umich.edu name: Rishindra Reddy, MD, MBA role: PRINCIPAL_INVESTIGATOR lat: 42.27756 lon: -83.74088 hasResults: False
nctId: NCT06384651 id: PRO00037789 briefTitle: Intraosseous vs. Intravenous Vancomycin Administration in Total Ankle Arthroplasty acronym: IOTAA overallStatus: RECRUITING date: 2023-12-13 date: 2027-04 date: 2027-12 date: 2024-04-25 date: 2024-04-25 name: The Methodist Hospital Research Institute class: OTHER briefSummary: The purpose of this study is to compare two different antibiotic regimens and techniques during total ankle arthroplasty (TAA).
Secondary Objective: Compare 30 day and 90 day post-operative complication rates (infection) between the control (standard IV administration of vancomycin) vs the interventional group (intraosseous administration of vancomycin). The investigators hypothesize that there will be no difference in complication (infection) rates between groups. conditions: Infections conditions: Ankle Arthritis studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study is a prospective, randomized, single-blinded, controlled trial. 20 patients in each treatment arm: 20 patients will be given IV vancomycin, 20 patients will be given IO vancomycin primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: single blind patient is blinded. Surgeon is not blinded. Lab technician measuring tissue concentrations are blinded. Research coordinator is not blinded. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Intraosseous Vancomycin Injection name: Intravenous Vancomycin measure: Systemic Sample Vancomycin Tissue Concentration - Start of Case measure: Systemic Sample Vancomycin Tissue Concentration - End of Case measure: Capsule or Synovium Sample Vancomycin Tissue Concentration measure: Distal Tibia Sample Vancomycin Tissue Concentration measure: Talar Bone Sample Vancomycin Tissue Concentration measure: 90 day post-operative wound complication and infection rates sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Houston Methodist Hospital status: RECRUITING city: Houston state: Texas zip: 77030 country: United States name: Thomas C Sullivan, BS role: CONTACT phone: 346-238-1603 email: tsullivan@houstonmethodist.org name: Jason S Ahuero, MD role: PRINCIPAL_INVESTIGATOR name: Kevin Varner, MD role: SUB_INVESTIGATOR name: Kwan J Park, MD role: SUB_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06384638 id: coconut periodontitis briefTitle: Coconut Oil in Treatment of Periodontitis overallStatus: COMPLETED date: 2022-02-15 date: 2024-01-16 date: 2024-02-09 date: 2024-04-25 date: 2024-04-25 name: Misr University for Science and Technology class: OTHER briefSummary: Virgin Coconut Oil (VCO) is a vegetable oil extracted from coconut fleshcontains unsaturated fatty acids in the form of oleic acid and linoleic acid and flavonoids which function as anti-inflammatory. Periodontitis is an inflammatory disease of the periodontal tissues with a high prevalence worldwide. The main etiology of plaque periodontitis is biofilm containing colonies of pathogenic microorganisms. The aim of the study is to evaluate and compare the effect of scaling and root debridement alone versus the use of topically applied coconut oil as adjunctive to scaling and root debridement in treatment of Stage II and III Grade B periodontitis. conditions: Periodontal Diseases studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 34 type: ACTUAL name: topical application of coconut oil name: scaling and debridement measure: clinical parameters measure: clinical parameters measure: Biological parameters sex: ALL minimumAge: 35 Years maximumAge: 60 Years stdAges: ADULT facility: Faculty of dentistry at MUST city: Giza zip: 02 country: Egypt lat: 30.00808 lon: 31.21093 hasResults: False
nctId: NCT06384625 id: 361378 briefTitle: Air Pollution Intervention for Cardiovascular Patients overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-02-01 date: 2025-02-01 date: 2024-04-25 date: 2024-04-25 name: University of Montana class: OTHER name: Providence Heart Institute briefSummary: This pilot study (n=20) is a prospective evaluation of the implementation of an indoor air pollution intervention among patients who have undergone recent percutaneous coronary intervention procedures. The intervention, called Air Improvement and Real-time Monitoring for Wellness through Interactive Strategies and Education (AIRWISE), is focused on improving indoor air quality through air filtration, education, and behavioral recommendations. All participants will receive the AIRWISE intervention with the objective of evaluating acceptance and use of the individual intervention components. This implementation study will inform the submission of a larger NIH proposal for a randomized trial. The central study hypothesis is that an intervention program with educational strategies and visual behavioral cues will increase knowledge and awareness of air pollution exposures among the participants and lead to improved intervention compliance. conditions: Coronary Heart Disease conditions: Cardiovascular Diseases conditions: Environmental Exposure studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 20 type: ESTIMATED name: AIRWISE measure: Evaluate the implementation of an indoor air pollution intervention. measure: Fine particulate matter (PM2.5) measure: Life's Essential 8 sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06384612 id: Adnan Menderes U briefTitle: The Effect Of The Use Of Pocket Cards In An Undergraduate Nursıng overallStatus: COMPLETED date: 2021-09-13 date: 2022-05-22 date: 2023-07-13 date: 2024-04-25 date: 2024-04-25 name: Aydin Adnan Menderes University class: OTHER briefSummary: The aim of this study is to examine the effect of the use of pocket cards by students taking the "Care of a Child with Special Needs" course on students' self-efficacy perceptions and course success.
2. H02. There is no significant difference between the course success scores of the students in the group who use pocket cards in the care of children with special needs course and the students in the group who do not use pocket cards. conditions: Student conditions: Self Efficacy studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: experimental primaryPurpose: OTHER masking: NONE count: 128 type: ACTUAL name: use of pocket cards measure: Self-Efficacy Perception Scale sex: ALL minimumAge: 18 Years maximumAge: 22 Years stdAges: ADULT facility: Bircan Kahraman Berberoğlu city: Efeler state: Aydin zip: 0900 country: Turkey hasResults: False
nctId: NCT06384599 id: CS-190 briefTitle: VT Cryoablation System Post-Market Clinical Follow-up (PMCF) Study overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2026-06-01 date: 2026-06-01 date: 2024-04-25 date: 2024-04-25 name: Adagio Medical class: INDUSTRY briefSummary: The PMCF is a prospective, single-arm, multi-center, controlled study of up to 130 patients designed to collect safety and performance data regarding the use of the Adagio VT Cryoablation System in the treatment of recurrent ventricular tachycardia. conditions: Ventricular Tachycardia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 130 type: ESTIMATED name: VT Cryoablation System measure: Primary Performance Endpoint measure: Primary Safety Endpoint measure: Secondary Performance Endpoint measure: Secondary Safety Endpoint sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Essex Cardiothoracic Centre city: Basildon state: Essex zip: SS16 5NL country: United Kingdom name: Neil Srinivasan role: CONTACT lat: 51.56844 lon: 0.45782 hasResults: False
nctId: NCT06384586 id: CD J8855 briefTitle: Investigation of Dietary Supplement Liquid Shot Products on Mental Energy, Cognition (Acuity),and Mood overallStatus: COMPLETED date: 2022-11-17 date: 2022-12-22 date: 2022-12-22 date: 2024-04-25 date: 2024-04-25 name: The Water Street Collective class: INDUSTRY name: HCD Research name: British American Tobacco (Investments) Limited briefSummary: This is a single center, randomized, double blind, placebo-controlled, crossover study to determine the acute effect of a developmental dietary supplement liquid shot product on cognitive task performance and perceived effect measures related to mood and mental energy. The study will be conducted in healthy participants. conditions: Cognition conditions: Mental Fatigue conditions: Mood studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: BASIC_SCIENCE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 45 type: ACTUAL name: Placebo shot name: Functional energy shot measure: Mental energy via Cognitive Demand Battery (CDB) Performance Index; for the functional energy shot versus placebo shot. measure: Mental energy via Cognitive Demand Battery (CDB) Accuracy score for the functional energy shot versus placebo shot. measure: Change in performance on Corsi blocks task for functional energy shot versus placebo measure: Change in performance on Rapid Visual Information Processing (RVIP) for functional energy shot versus placebo measure: Change in performance on Numeric working memory for functional energy shot versus placebo measure: Change in performance on Serial subtraction task for functional energy shot versus placebo measure: Change in Mood via Visual Analogue Scales (VAS) during Cognitive Demand Battery (CDB), for functional energy shot versus placebo measure: Change in physiological state via Profile Of Mood States (POMS) during Cognitive Demand Battery (CDB), for functional energy shot versus placebo sex: ALL minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT facility: Schlesinger Group New Jersey city: Iselin state: New Jersey zip: 08330 country: United States lat: 40.57538 lon: -74.32237 hasResults: False
nctId: NCT06384573 id: DIAN-TU-003 id: The Alzheimer's Association type: OTHER_GRANT domain: DIAN-TU-OLE-21-725093 briefTitle: DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease acronym: DIAN-TU overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2029-11 date: 2029-11 date: 2024-04-25 date: 2024-04-25 name: Washington University School of Medicine class: OTHER name: Alzheimer's Association name: Eisai Inc. briefSummary: This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to external controls, if amyloid plaque as measured by amyloid PET can be fully removed in DIAD, and the effects of amyloid removal on biomarkers of disease progression. conditions: Alzheimer's Disease conditions: Dementia conditions: Alzheimer's Disease, Familial studyType: INTERVENTIONAL phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 65 type: ESTIMATED name: lecanemab measure: The primary endpoint for the final analysis is the time to recurrent progression of Clinical Dementia Rating - Sum of Boxes (CDR-SB). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Alabama in Birmingham city: Birmingham state: Alabama zip: 35294 country: United States name: Erik Roberson role: PRINCIPAL_INVESTIGATOR lat: 33.52066 lon: -86.80249 facility: University of California San Diego Medical Center city: La Jolla state: California zip: 92037 country: United States name: Doug Galasko role: PRINCIPAL_INVESTIGATOR lat: 32.84727 lon: -117.2742 facility: Indiana University School of Medicine city: Indianapolis state: Indiana zip: 46202 country: United States name: Jared Brosch role: PRINCIPAL_INVESTIGATOR lat: 39.76838 lon: -86.15804 facility: Washington University in St. Louis city: Saint Louis state: Missouri zip: 63110 country: United States name: Barbara Snider role: PRINCIPAL_INVESTIGATOR lat: 38.62727 lon: -90.19789 facility: University of Pittsburgh city: Pittsburgh state: Pennsylvania zip: 15213 country: United States name: Sarah Berman role: PRINCIPAL_INVESTIGATOR lat: 40.44062 lon: -79.99589 facility: University of Washington city: Seattle state: Washington zip: 98195 country: United States name: Suman Jayadev role: PRINCIPAL_INVESTIGATOR lat: 47.60621 lon: -122.33207 facility: Neuroscience Research Australia city: Randwick state: New South Wales zip: 2031 country: Australia name: William Brooks role: PRINCIPAL_INVESTIGATOR lat: -33.91439 lon: 151.24895 facility: The National Hospital for Neurology and Neurosurgery city: London state: Greater London zip: WC1B 3BG country: United Kingdom name: Catherine Mummery role: CONTACT lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06384560 id: 2023-508707-20-00 briefTitle: Neoadjuvant Triple Treatment for Borderline Resectable Pancreatic Cancer (PREOPANC-5) acronym: PREOPANC-5 overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2028-03 date: 2028-03 date: 2024-04-25 date: 2024-04-25 name: Amsterdam UMC, location VUmc class: OTHER name: Maastricht University Medical Center name: Erasmus Medical Center name: St. Antonius Hospital briefSummary: Since patients with borderline resectable pancreatic cancer (BRPC) have a limited life expectancy, it is important to improve treatment strategies. Therefore, the objective of this study is to investigate whether neoadjuvant triple treatment chemotherapy, immunotherapy and radiotherapy, followed by surgery and chemotherapy and immunotherapy survival in patients with BRPC. conditions: Borderline Resectable Pancreatic Cancer studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 66 type: ESTIMATED name: Pembrolizumab measure: Percentage of patients with progression free survival at 18 months (RECIST 1.1) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06384547 id: VRDN-001-303 briefTitle: A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-05 date: 2026-01 date: 2024-04-25 date: 2024-04-25 name: Viridian Therapeutics, Inc. class: INDUSTRY briefSummary: The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in patients with thyroid eye disease (TED). The primary objective of this clinical trial is to evaluate the safety and tolerability of VRDN-001 in patients with TED. conditions: Thyroid Eye Disease studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A randomized, active controlled, safety and tolerability study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in participants with thyroid eye disease (TED) primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 212 type: ESTIMATED name: VRDN-001 10 mg/kg name: VRDN-001 3 mg/kg measure: Treatment Emergent Adverse Event (TEAE) incidence rate measure: Change from baseline in proptosis in the study eye as measured by exophthalmometer at Week 15 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: United Medical Research Institute city: Inglewood state: California zip: 90301 country: United States name: James Peace, MD role: CONTACT phone: 310-645-4673 lat: 33.96168 lon: -118.35313 hasResults: False
nctId: NCT06384534 id: PVD_6MWD_SOT briefTitle: Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy in Pulmonary Vascular Disease (PVD) overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2025-11 date: 2024-04-25 date: 2024-04-25 name: University of Zurich class: OTHER briefSummary: The investigators aim to study the effect of SOT in Swiss residents with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH). conditions: Pulmonary Vascular Disorder conditions: Chronic Thromboembolic Pulmonary Hypertension conditions: Pulmonary Arterial Hypertension studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Each participant is its own control primaryPurpose: OTHER masking: NONE count: 28 type: ESTIMATED name: 6-minute walk distance (6MWD) test on ambient air name: 6-minute walk distance test with supplemental oxygen measure: 6-minute walk distance (6MWD) with supplemental oxygen therapy (SOT) vs. ambient air measure: SpO2 at rest and peak 6MWD with SOT vs. ambient air measure: Heart rate at rest and peak 6MWD with SOT vs. ambient air measure: Borg dyspnea scale at rest and peak 6MWD with SOT vs. ambient air measure: Borg leg fatigue scale at rest and peak 6MWD with SOT vs. ambient air measure: Blood pressure at rest and peak 6MWD with SOT vs. ambient air sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Zürich city: Zurich zip: 8091 country: Switzerland name: Silvia Ulrich, Prof. Dr. role: CONTACT phone: 0041 44 255 22 20 email: silvia.ulrich@usz.ch name: Mona Lichtblau, Dr. role: CONTACT phone: +41442552220 email: mona.lichtblau@usz.ch name: Silvia Ulrich, Prof. Dr. role: PRINCIPAL_INVESTIGATOR lat: 47.36667 lon: 8.54999 hasResults: False